<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ssmu</journal-id><journal-title-group><journal-title xml:lang="ru">Бюллетень сибирской медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of Siberian Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-0363</issn><issn pub-type="epub">1819-3684</issn><publisher><publisher-name>Siberian State Medical University, the Ministry of Healthcare of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20538/1682-0363-2019-4-16-25</article-id><article-id custom-type="elpub" pub-id-type="custom">ssmu-2551</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Взаимосвязь динамики сывороточных концентраций интерлейкина-1β, интерлейкина-6 и интерлейкина-10 с клиническими данными в остром периоде ишемического инсульта в зависимости от стратегии реперфузионной терапии</article-title><trans-title-group xml:lang="en"><trans-title>Interrelation of the dynamics of serum concentrations of interleukin-1β, interleukin-6 and interleukin-10 with clinical data in acute ischemic stroke and the strategy of reperfusion therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3462-444X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Быкова</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Bykova</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-невролог, неврологическое отделение для больных с острым нарушением мозгового кровообращения,</p><p>614000, г. Пермь, ул. Ким, 2</p></bio><bio xml:lang="en"><p>Neurologist, Department of Neurology,</p><p> 2, Kim Str., Perm, 614000</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6061-8118</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кулеш</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulesh</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, доцент, кафедра неврологии,</p><p>614000, г. Пермь, ул. Петропавловская, 26</p></bio><bio xml:lang="en"><p>DM, Associate Professor, Department of Neurology, </p><p> 26, Petropavlovskaya Str., Perm, 614990</p></bio><email xlink:type="simple">aleksey.kulesh@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3785-1154</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кайлева</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kayleva</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-рентгенолог,</p><p>614000, г. Пермь, ул. Ким, 2</p></bio><bio xml:lang="en"><p>Radiologist, Department of Radiology,</p><p>2, Kim Str., Perm, 614000</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2173-2724</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куклина</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuklina</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р биол. наук, вед. науч. сотрудник, лаборатория иммунорегуляции,</p><p>614000, г. Пермь, ул. Голева, 13 </p></bio><bio xml:lang="en"><p>Leading Researcher,</p><p>13, Goleva Str., Perm, 614081</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6310-9316</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шестаков</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shestakov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, зав. кафедрой неврологии,</p><p>614000, г. Пермь, ул. Петропавловская, 26</p></bio><bio xml:lang="en"><p>DM, Professor, Head of the Department of Neurology, </p><p>26, Petropavlovskaya Str., Perm, 614990</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Городская клиническая больница (ГКБ) № 4</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Perm City Hospital № 4</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Пермский государственный медицинский университет им. академика Е.А. Вагнера (ПГМУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Perm State Medical University named after Academician E.A. Wagner (PSMU)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Институт экологии и генетики микроорганизмов Уральского отделения Российской академии наук − филиал Федерального государственного бюджетного учреждения науки Пермского федерального исследовательского центра Уральского отделения Российской академии наук (ИЭГМ УРО РАН)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Ecology and Genetics of Microorganisms of the Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>14</day><month>01</month><year>2020</year></pub-date><volume>18</volume><issue>4</issue><fpage>16</fpage><lpage>25</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Быкова А.Ю., Кулеш А.А., Кайлева Н.А., Куклина Е.М., Шестаков В.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Быкова А.Ю., Кулеш А.А., Кайлева Н.А., Куклина Е.М., Шестаков В.В.</copyright-holder><copyright-holder xml:lang="en">Bykova A.Y., Kulesh A.A., Kayleva N.A., Kuklina E.M., Shestakov V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://bulletin.ssmu.ru/jour/article/view/2551">https://bulletin.ssmu.ru/jour/article/view/2551</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить взаимосвязь динамики сывороточных концентраций интерлейкина-1β, интерлейкина-6 и интерлейкина-10 с клиническими данными в остром периоде ишемического инсульта в зависимости от стратегии реперфузионной терапии.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включены 28 пациентов в возрасте от 47 до 87 (64 ± 13) лет, в том числе 21 мужчина и 7 женщин. У всех пациентов в остром периоде ишемического инсульта, 14 из которых проводилась внутривенная тромболитическая терапия, оценена концентрация интерлейкина-1β, интерлейкина-6 и интерлейкина-10 при поступлении, на 3-и и 10-е сут заболевания. </p></sec><sec><title>Результаты</title><p>Результаты. Концентрация интерлейкина-1β и интерлейкина-6 снижается в течение острейшего периода инсульта. Концентрация интерлейкина-10 остается неизменной на протяжении первых 10 сут с момента развития мозговой катастрофы. При проведении тромболизиса отмечается более значимое снижение концентрации интерлейкина-1β в острейшем периоде инсульта, тогда как у пациентов без реперфузии наблюдается снижение концентрации интерлейкина-6 с 1-го по 10-е сут заболевания. Концентрация цитокинов ассоциирована с возрастом, параметрами липидного спектра, выраженностью каротидного атеросклероза, гипертрофией миокарда и насосной функцией сердца. Лишь в подгруппе тромболизиса зафиксированы корреляции концентрации цитокинов с величиной систолического артериального давления при поступлении, концентрацией гемоглобина, общего холестерина и липопротеинов высокой плотности, гематокритом, степенью стенозирования контралатеральной сонной артерии, фракцией выброса сердца и количеством антигипертензивных препаратов, назначенных в стационаре. Концентрация интерлейкина-6 на 10-е сут связана с тяжестью инсульта при поступлении в стационар, а уровень интерлейкина-10 на 3-и сут заболевания − с мобильностью пациентов при выписке.</p></sec><sec><title>Выводы</title><p>Выводы. В острейшем периоде инсульта происходит снижение провоспалительной активности сыворотки крови, более выраженное у пациентов, которым проведен системный тромболизис. Концентрация интерлейкина-1β, интерлейкина-6 и интерлейкина-10 ассоциирована с широким спектром параметров, характеризующих сердечно-сосудистый и функциональный статус, причем паттерн данных ассоциаций отличается в зависимости от стратегии реперфузионной терапии.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the relationship between the dynamics of serum concentrations of interleukin-1β, interleukin-6 and interleukin-10 with clinical data in the acute period of ischemic stroke, and the strategy of reperfusion therapy.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. In 28 patients with acute ischemic stroke, half of whom underwent intravenous thrombolysis, the concentration of interleukin-1β, interleukin-6 and interleukin-10 was assessed at admission, on the 3rd and 10th day of the disease.</p></sec><sec><title>Results</title><p>Results. The concentration of interleukin-1β and interleukin-6 decreases during the acute period of stroke. The concentration of interleukin-10 remains unchanged for the first 10 days since the development of stroke. When thrombolysis is performed, there is a more significant decrease in interleukin-1β concentration in the hyperacute period of stroke, whereas in patients without reperfusion there is a decrease in interleukin-6 concentration from 1 to 10 days. The concentration of cytokines is associated with age, lipid spectrum, severity of carotid atherosclerosis, myocardial hypertrophy and injection fraction of the heart. Only in the subgroup of thrombolysis, correlations of cytokine concentrations with systolic blood pressure at admission, hemoglobin concentration, total cholesterol and high-density lipoproteins, hematocrit, degree of stenosis of the contralateral carotid artery, injection fraction and the number of antihypertensive drugs prescribed in the hospital were recorded. The concentration of interleukin-6 at day 10 is associated with the severity of stroke at admission, and the level of IL-10 on day 3 of the disease, with the mobility of patients at discharge.</p></sec><sec><title>Conclusions</title><p>Conclusions. In the hyperacute period of stroke, there is a decrease in the pro-inflammatory activity of blood serum, more pronounced in patients undergoing systemic thrombolysis. Concentrations of interleukin1β, interleukin-6 and interleukin-10 are associated with a wide range of parameters characterizing the cardiovascular and functional status, and the pattern of these associations differs depending on the reperfusion therapy strategy. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>инсульт</kwd><kwd>тромболизис</kwd><kwd>цитокины</kwd><kwd>нейровоспаление</kwd><kwd>прогноз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>stroke</kwd><kwd>thrombolysis</kwd><kwd>cytokines</kwd><kwd>neuroinflammation</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Veltkamp R., Gill D. Clinical trials of immunomodulation in ischemic stroke. Neurotherapeutics. 2016; 13 (4): 791–800. DOI: 10.1007/s13311-016-0458-y.</mixed-citation><mixed-citation xml:lang="en">Veltkamp R., Gill D. Clinical trials of immunomodulation in ischemic stroke. Neurotherapeutics. 2016; 13 (4): 791–800. DOI: 10.1007/s13311-016-0458-y.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tuttolomondo A., Raimondo D., di Sciacca R., Pinto A., Licata G. Inflammatory cytokines in acute ischemic stroke. Curr. Pharm. Des. 2008; 14 (33): 3574–3589.</mixed-citation><mixed-citation xml:lang="en">Tuttolomondo A., Raimondo D., di Sciacca R., Pinto A., Licata G. Inflammatory cytokines in acute ischemic stroke. Curr. Pharm. Des. 2008; 14 (33): 3574–3589.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dziedzic T. Systemic inflammation as a therapeutic target in acute ischemic stroke. Expert. Rev. Neurother. 2015; 15 (5): 523–531. DOI: 10.1586/14737175.2015.1035712.</mixed-citation><mixed-citation xml:lang="en">Dziedzic T. Systemic inflammation as a therapeutic target in acute ischemic stroke. Expert. Rev. Neurother. 2015; 15 (5): 523–531. DOI: 10.1586/14737175.2015.1035712.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Minami M., Katayama T., Satoh M. Brain cytokines and chemokines: roles in ischemic injury and pain. J. Pharmacol. Sci. 2006; 100 (5): 461–470.</mixed-citation><mixed-citation xml:lang="en">Minami M., Katayama T., Satoh M. Brain cytokines and chemokines: roles in ischemic injury and pain. J. Pharmacol. Sci. 2006; 100 (5): 461–470.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Tobin M.K., Bonds J.A., Minshall R.D., Pelligrino D.A., Testai F.D., Lazarov O. Neurogenesis and inflammation after ischemic stroke: what is known and where we go from here. J. Cereb. Blood Flow Metab. 2014; 34 (10): 1573–1584. DOI: 10.1038/jcbfm.2014.130.</mixed-citation><mixed-citation xml:lang="en">Tobin M.K., Bonds J.A., Minshall R.D., Pelligrino D.A., Testai F.D., Lazarov O. Neurogenesis and inflammation after ischemic stroke: what is known and where we go from here. J. Cereb. Blood Flow Metab. 2014; 34 (10): 1573–1584. DOI: 10.1038/jcbfm.2014.130.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Banwell V., Sena E.S., Macleod M.R. Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J. Stroke Cerebrovasc. Dis. 2009; 18 (4): 269–276. DOI: 10.1016/j.jstrokecerebrovasdis.2008.11.009.</mixed-citation><mixed-citation xml:lang="en">Banwell V., Sena E.S., Macleod M.R. Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J. Stroke Cerebrovasc. Dis. 2009; 18 (4): 269–276. DOI: 10.1016/j.jstrokecerebrovasdis.2008.11.009.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bonaventura A., Liberale L., Vecchiй A., Casula M., Carbone F., Dallegri F., Montecucco F. Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. Int. J. Mol. Sci. 2016; 17 (12): e1967. DOI: 10.3390/ijms17121967.</mixed-citation><mixed-citation xml:lang="en">Bonaventura A., Liberale L., Vecchiй A., Casula M., Carbone F., Dallegri F., Montecucco F. Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. Int. J. Mol. Sci. 2016; 17 (12): e1967. DOI: 10.3390/ijms17121967.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yasuda Y., Shimoda T., Uno K., Tateishi N., Furuya S., Tsuchihashi Y., Kawai Y., Naruse S., Fujita S. Temporal and sequential changes of glial cells and cytokine expression during neuronal degeneration after transient global ischemia in rats. J. Neuroinflammation. 2011; 22 (8): 70. DOI: 10.1186/1742-2094-8-70.</mixed-citation><mixed-citation xml:lang="en">Yasuda Y., Shimoda T., Uno K., Tateishi N., Furuya S., Tsuchihashi Y., Kawai Y., Naruse S., Fujita S. Temporal and sequential changes of glial cells and cytokine expression during neuronal degeneration after transient global ischemia in rats. J. Neuroinflammation. 2011; 22 (8): 70. DOI: 10.1186/1742-2094-8-70.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Кулеш А.А., Куклина Е.М., Шестаков В.В. Взаимосвязь цитокиново-нейротрофического профиля с когнитивным и функциональным статусом в остром периоде ишемического инсульта. Вестник уральской медицинской академической науки. 2016; 1 (56): 51–55.</mixed-citation><mixed-citation xml:lang="en">Kulesh A.A., Kuklina E.M., Shestakov V.V. Interrelation of the cytokine-neurotrophic profile with cognitive and functional status in the acute period of ischemic stroke. Journal of Ural Medical Academic Science. 2016; 1 (56): 51–55 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Кулеш А.А., Дробаха В.Е., Шестаков В.В., Некрасова И.В., Куклина Е.М. Нейровоспалительные, нейродегенеративные и структурные церебральные маркеры основных клинических вариантов постинсультных когнитивных нарушений в остром периоде ишемического инсульта. Вестник Российской академии медицинских наук. 2016; 71 (4): 304–312.</mixed-citation><mixed-citation xml:lang="en">Kulesh A.A., Drobaha V.E., Shestakov V.V., Nekrasova I.V., Kuklina E.M. Neuro-inflammatory, neurodegenerative and structural cerebral markers of the main clinical variants of post-stroke cognitive impairment in the acute period of ischemic stroke. Annals of the Russian Academy ofMedical Sciences 2016; 71 (4): 304–312 (in Russ.). DOI: 10.15690/vramn685.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Кулеш А.А., Дробаха В.Е., Кайлева Н.А., Голосова Ю.А., Шестаков В.В. Возможности перфузионной шкалы ASPECTS в прогнозировании эффективности внутривенной тромболитической терапии. Неврология, нейропсихиатрия, психосоматика. 2017; 9 (3): 10–17. DOI: 10.14412/2074-2711-2017-3-10-17.</mixed-citation><mixed-citation xml:lang="en">Kulesh A.A., Drobaha V.E., Kayleva N.A., Golosova Ju.A., Shestakov V.V. The possibilities of the ASPECTS perfusion scale in predicting the effectiveness of intravenous thrombolytic therapy. Neurology, Neuropsychiatry, Psychosomatics. 2017; 9 (3): 10–17 (in Russ.). DOI: 10.14412/2074-2711-2017-3-10-17.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mizuma A., Yenari M.A. Anti-inflammatory targets for the treatment of reperfusion injury in stroke. Collection 2017. Anti-inflammatory. Front. Neurol. 2017; 7 (8): 467. DOI: 10.3389/fneur.2017.00467.</mixed-citation><mixed-citation xml:lang="en">Mizuma A., Yenari M.A. Anti-inflammatory targets for the treatment of reperfusion injury in stroke. Collection 2017. Anti-inflammatory. Front. Neurol. 2017; 7 (8): 467. DOI: 10.3389/fneur.2017.00467.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lenglet S., Montecucco F., Denes A., Coutts G., Pinteaux E., Mach F., Schaller K., Gasche Y., Copin J.C. Recombinant tissue plasminogen activator enhances microglial cell recruitment after stroke in mice. J. Cereb. Blood Flow Metab. 2014; 34 (5): 802–812. DOI: 10.1038/jcbfm.2014.9.</mixed-citation><mixed-citation xml:lang="en">Lenglet S., Montecucco F., Denes A., Coutts G., Pinteaux E., Mach F., Schaller K., Gasche Y., Copin J.C. Recombinant tissue plasminogen activator enhances microglial cell recruitment after stroke in mice. J. Cereb. Blood Flow Metab. 2014; 34 (5): 802–812. DOI: 10.1038/jcbfm.2014.9.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ye L., Cai R., Yang M., Qian J., Hong Z. Reduction of the systemic inflammatory induced by acute cerebral infarction through ultra-early thrombolytic therapy. Exp. Ther. Med. 2015; 10 (4):1493–1498. DOI: 10.3892/etm.2015.2672.</mixed-citation><mixed-citation xml:lang="en">Ye L., Cai R., Yang M., Qian J., Hong Z. Reduction of the systemic inflammatory induced by acute cerebral infarction through ultra-early thrombolytic therapy. Exp. Ther. Med. 2015; 10 (4):1493–1498. DOI: 10.3892/etm.2015.2672.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gregersen I., Holm S., Dahl T.B., Halvorsen B., Aukrust P. A focus on inflammation as a major risk factor for atherosclerotic cardiovascular diseases. Expert. Rev. Cardiovasc. Ther. 2016; 14 (3): 391–403. DOI: 0.1586/14779072.2016.1128828.</mixed-citation><mixed-citation xml:lang="en">Gregersen I., Holm S., Dahl T.B., Halvorsen B., Aukrust P. A focus on inflammation as a major risk factor for atherosclerotic cardiovascular diseases. Expert. Rev. Cardiovasc. Ther. 2016; 14 (3): 391–403. DOI: 0.1586/14779072.2016.1128828.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kumar P., Yadav A.K., Misra S., Kumar A., Chakravarty K., Prasad K. Role of Interleukin-10 (-1082A/G) gene polymorphism with the risk of ischemic stroke: a meta-analysis. Neurol. Res. 2016; 38 (9): 823–830. DOI: 10.1080/01616412.2016.1202395.</mixed-citation><mixed-citation xml:lang="en">Kumar P., Yadav A.K., Misra S., Kumar A., Chakravarty K., Prasad K. Role of Interleukin-10 (-1082A/G) gene polymorphism with the risk of ischemic stroke: a meta-analysis. Neurol. Res. 2016; 38 (9): 823–830. DOI: 10.1080/01616412.2016.1202395.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">McDonough A., Weinstein J.R. Neuroimmune response in ischemic preconditioning. Neurotherapeutics. 2016; 13 (4): 748–761. DOI: 10.1007/s13311-016-0465-z. 18. Boehme A.K., Kapoor N., Albright K.C., Lyerly M.J., Rawal P.V., Bavarsad Shahripour R., Alvi M., Houston J.T., Sisson A., Beasley T.M., Alexandrov A.W., Alexandrov A.V., Miller D.W. Predictors of systemic inflammatory response syndrome in ischemic stroke undergoing systemic thrombolysis with intravenous tissue plasminogen activator. J. Stroke Cerebrovasc. Dis. 2014; 23 (4): e271–276. DOI: 10.1016/j.jstrokecerebrovasdis.2013.11.022.</mixed-citation><mixed-citation xml:lang="en">McDonough A., Weinstein J.R. Neuroimmune response in ischemic preconditioning. Neurotherapeutics. 2016; 13 (4): 748–761. DOI: 10.1007/s13311-016-0465-z. 18. Boehme A.K., Kapoor N., Albright K.C., Lyerly M.J., Rawal P.V., Bavarsad Shahripour R., Alvi M., Houston J.T., Sisson A., Beasley T.M., Alexandrov A.W., Alexandrov A.V., Miller D.W. Predictors of systemic inflammatory response syndrome in ischemic stroke undergoing systemic thrombolysis with intravenous tissue plasminogen activator. J. Stroke Cerebrovasc. Dis. 2014; 23 (4): e271–276. DOI: 10.1016/j.jstrokecerebrovasdis.2013.11.022.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia J.M., Stillings S.A., Leclerc J.L., Phillips H., Edwards N.J., Robicsek S.A., Hoh B.L, Blackburn S., Dorй S. Role of Interleukin-10 in acute brain injuries. Front. Neurol. 2017; 12 (8): 244. DOI: 10.3389/fneur.2017.00244.</mixed-citation><mixed-citation xml:lang="en">Garcia J.M., Stillings S.A., Leclerc J.L., Phillips H., Edwards N.J., Robicsek S.A., Hoh B.L, Blackburn S., Dorй S. Role of Interleukin-10 in acute brain injuries. Front. Neurol. 2017; 12 (8): 244. DOI: 10.3389/fneur.2017.00244.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
